ArticleJournal of cancer research and clinical oncology2023
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years.
Sabine Kürzel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.